Brought to you by 
PharmAbcine's Series A round brings in $6mm
28 Sep 2009
Executive Summary
South Korea's PharmAbcine (monoclonal antibodies) raised $6mm through its Series A round that was co-led by Caduceus Asia Partners (managed by OrbiMed) and the Novartis Korea Venture Fund (NKVF). Green Cross, Tong Yang, and Saehan Venture Fund also participated. OrbiMed, NKVF, and Green Cross all take seats on the company's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PharmAbcine's Series A round brings in $6mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice